3 Study years are available on line and the November issue of arthritis & rheumatism, a newspaper published by Wiley-Blackwell, on behalf of the American College of Rheumatology.
Juvenile idiopathic arthritis (MIC), one of the most common rheumatic diseases in children causes a significant pain and disability fonctionnelle.Selon study data working group 2008 arthritis, there are close to 300,000 children at United States with a form any arthritis juvénile.Spectacle previous studies that JIA patients can undergo a physical disability the growth and development depend on the severity of chronic inflammation, long-term illness, and more great functional joint participation.
"A realistic treatment for patients JIA goal should include a treatment aimed at reducing inflammation to minimize disability and related disease, growth impairment" said Edward Giannini, masters, M.sc Dr. Giannini and colleagues conducted a study lead author 3 years non-randomized multicentre registry used 594 patients (90%) or systemic JIA treated with etanercept, etanercept plus MTX or MTX only.
Participants aged from 2 to 18, enrolled in the registry were treated with etanercept twice a week at 0.4 mg/kg dose or once a week at a dose of 0.8 mg/kg. Height, weight and BMI for each patient recorded initially years 1, 2, 3 and comparison with the Centers for Disease Control and Prevention, graphical standardized United States growth to obtain the percentiles.
The authors reported that average height of etanercept Group significantly increased by 4.8 per year 3 percentiles.For those of the etanercept more group MTX, a significant increase in the average height for years 1, 2 and 3 also recorded a-4, 3.3 and percentile 5.6 points, significant respectivement.Augmentations similar percentile of weight at the age of 1, 2 and 3, respectively, were observed in group only etanercept (7.4, 10.0 and 13.0) and in the etanercept more group MTX (2.9, 6.9 and 8.4) .IMC percentiles also increased significantly during the period of three years, ranging from 9.6 to 13.8 points percentile in the group only etanercept and 2.1 to 5.2 percentiles in the etanercept MTX group.
"Studies have shown that growth retardation is associated with systemic inflammation and is a potentially permanent complication of MIC", explained Dr. Giannini. "Restore normal growth development is a relevant goal of anti-inflammatory treatment in JIA patients and our study has shown an increase in significant height, weight and BMI percentile for those treated with the etanercept, alone or in combination with MTX."Significant change in the measurement of growth were observed for patients receive treatment only MTX.
Editor's note: this article is not intended to provide medical advice, diagnosis or treatment.
Source of the story:
The story above is reproduced (with drafting adaptations by staff at PharmaLive.com) materials provided by Wiley - Blackwell, via AlphaGalileo.
Reference of the review:
Edward h. Giannini, Norman t. Ilowite, Daniel j. Lovell, Carol a. Wallace, c. Egla Rabinovich, Andreas Reiff, Gloria Higgins, Beth Gottlieb, Yun Chon, Nan Zhang, Scott w. Baumgartner.Effects of pretreatment of etanercept long-term growth in children suffering from certain categories of juvenile idiopathic arthritis .the ' arthritis & rheumatism, 2010; 62 (11): 3 259 DOI: 10.1002/art.27682Note: If no author is given, the source is cited for this.
No comments:
Post a Comment